BetterInfo on Women's PrEP Choices and Outcomes in Malawi

Recruiting N/A Interventional Study
Long-acting Injectable Cabotegravir for PrEP Oral Pre-Exposure Prophylaxis (PrEP)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 110
Sex
Female
Study type
Interventional
Purpose
Prevention
Participants needed
384 (estimated)
Sponsor
Johns Hopkins Bloomberg School of Public Health · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to understand PrEP user choices, preferences and implementation impact of the roll-out of long-acting injectable PrEP alongside oral PrEP among women in Blantyre, Malawi.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: The population for this research includes women aged 18 years or older at risk of HIV who initiated injectable or oral PrEP at one of the 20 Blantyre sites supported through PathToScale. PathToScale supports various types of facilities including public health clinics, drop-in ce…
Contacts

Amal Abdulrahman, MSPH

+ 1 443-983-4376

aabdul23@jh.edu

CONTACT

Sheree Schwartz, PhD, MPH

+1 443-983-2464

sschwartz@jhu.edu

CONTACT